Earnings this week : March 17 - 21, 25 (wk 12)

Monday (March 17)

• Morning: SAIC
• Afternoon: GETY LPRO

Tuesday (March 18)

• Morning: HUYA BEKE TME GDS
• Afternoon: ZTO

Wednesday (March 19)

• Morning: GIS KC OLLI SIG SRAD
• Afternoon: FIVE WS

Thursday (March 20) 

• Morning: ASO ACN CAL CMC DRI DBI FDS JBL PDD SCVL TITN ZK
• Afternoon: FDX KLC LEN LAZR MU NKE CURV

Friday (March 21)

• Morning: NIO
• Afternoon: CCL

Insider Trading Fri 3/14/25

Notable purchases -- CEO adds to PSEC; notable sales -- Chief Commercial Officer active in CYTK

Buyers

• AGM Director bought 1,000 shares of Class C Non-Voting Common Stock worth approximately $196K.
• ARCB Chief Financial Officer bought 700 shares at $74.89 worth ~$52K.
• ARES Director bought 10,000 shares of Class A common stock at $141.00 to $141.49 worth approximately $1.4 mln.
• CIM Director bought 12,500 shares at $13.28 - $13.40 worth approximately $166K.
• CRGY Director bought 30,000 shares of Class A Common Stock at $10.30 - $10.75 worth approximately $317K.
• DK Chairman of the Board and one (1) Director bought 6,780 combined shares worth approximately $99K.
• FRST Director bought 10,000 shares at $9.94 - $10.00 worth approximately $100K.
• LYB Director bought 3,750 Class A Ordinary Shares at $72.04 - $72.06 worth approximately $270K.
• ONTF 10% owner Lynrock Lake and one (1) Director bought 122,766 shares combined at $5.54 - $5.84 worth approximately $696K.
• PSEC Chief Executive Officer bought 2,000,000 shares worth approximately $8.6 mln.
• PTEN President / Chief Executive Officer bought 25,000 shares at $7.88 - $7.89 worth approximately $197K.
• RAPP Chief Financial Officer and one (1) Director bought 16,000 shares combined worth approximately $162K.
• RF Director bought 2,300 shares at $21.175 worth approximately $49K.
• TNL President & Chief Executive Officer bought 2,000 shares at $46.64 - $46.66 worth ~$93K.
• UAN 10% owner Carl Icahn bought another 11,345 common units at $74.56 - $74.80 worth approximately $847K.
• VG Chief Executive Officer / Founder and Executive Co-Chairman Michael Sabel, Executive Co-Chairman / Founder Robert Pender, and one (1) Director bought 512,000 shares of Class A Common Stock at $9.60 - $10.88 worth nearly $5.3 mln.
• WSC Chief Operating Officer bought 5,000 shares at $29.14 - $29.15 worth approximately $146K.
• ZYME 10% owner bought 1,081,980 shares at $11.11 - $12.55 worth approximately $13.1 mln.

Sellers

• AR Senior Vice President - Accounting and Chief Accounting Officer sold 9,830 shares at $35.60 worth approximately $350K.
• CYTK EVP, Chief Commercial Officer sold 26,771 shares at $43.62 worth approximately $1.2 mln.
• FNA 10% owner MVM Partners sold 1,044,295 shares at $13.01 - $13.065 worth approximately $13.6 mln.
• HURN Director sold 3,067 shares at $143.01 - $145,51 worth approximately $442K.

MeiraGTx (MGTX) $200M deal with Hologen AI for Parkinson's therapy

 

 

 

 

 

 

IPO: June 8, 2018

Hologen AI commits up to $430M to help take MeiraGTx's Parkinson's gene therapy through phase 3 and beyond

MeiraGTx will partner with Hologen AI to leverage its multimodal generative AI (genAI) models to accelerate Phase III development of the biotech's AAV-GAD gene therapy for Parkinson’s disease. 

The therapy, dubbed AAV-GAD, delivers a gene that codes for the enzyme that makes the neurotransmitter GABA, which is implicated in the characteristic motor dysfunction of Parkinson’s. A small-scale phase 2 readout last October showed that AAV-GAD was able to improve patients' motor ability and quality of life.

Details of the agreement 

MeiraGTx will receive an upfront cash payment of $200 million from Hologen, and together, the partners will launch a joint venture called Hologen Neuro AI. The genAI firm will also contribute $230 million in funding for the JV, which will shepherd AAV-GAD through development to commercialisation. The capital will help support other early-stage clinical programmes targeting the central nervous system (CNS), such as AAV-BDNF for genetic obesity. 

MeiraGTx will retain 30% ownership in Hologen Neuro AI and take the lead on all clinical development and manufacturing. It will form exclusive clinical and commercial manufacturing supply agreements with the JV. 

In turn, Hologen will use its genAI tech to optimise MeiraGTx's manufacturing practices, while gaining a minority stake in the manufacturing subsidiary and contributing to annual funding. 

About Hologen 

Hologen Limited is a world-leading developer of generative AI capabilities for clinical medicine and pharmaceutical drug development. 

The company emerged as a spin-out from University College London and Kings College London. It is privately held.

For more information, please visit www.hologen.ai

==-2seventy bio, Inc. (TSVT) to be acquired by Bristol Myers Squibb (BMY)

 

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 million net of estimated cash. The deal represents an 88% premium to the closing price of $2.66 on March 7, 2025.

“A year ago, 2seventy decided to exclusively focus on unlocking the value of Abecma, with the goal of delivering more time for people living with multiple myeloma and maximizing value for all stakeholders,” said Chip Baird, chief executive officer, 2seventy bio. “The strategic rationale for this acquisition is clear and today’s announcement represents the culmination of the journey for 2seventy bio. We believe that Abecma will continue to benefit from BMS’ experience and resources to ensure this important therapy is delivered to patients who need it. I would like to express my deep gratitude for current and past 2seventy team members and more broadly the dedicated community of patients, scientists, providers and partners that helped take cell and gene therapy from a complicated idea to reality for patients.”